Amgen Inc. Available-for-sale Securities, Gross Unrealized Loss
Amgen Inc. (AMGN) reported Available-for-sale Securities, Gross Unrealized Loss of $54.00 million for the 3-month period ending 2011-03-31, per its 10-Q filed 2011-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2011-05-10
- Amgen Inc. available-for-sale securities, gross unrealized loss for the quarter ending 2011-03-31 was $54.00M.
- Amgen Inc. available-for-sale securities, gross unrealized loss for the quarter ending 2010-12-31 was $35.00M.
- Amgen Inc. available-for-sale securities, gross unrealized loss for the quarter ending 2010-09-30 was $25.00M.
- Amgen Inc. available-for-sale securities, gross unrealized loss for fiscal 2009 was $21.00M.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month | Available-for-sale Securities, Gross Unrealized Loss 12 month as first filed |
|---|---|---|---|---|---|
| 2011-03-31 | $54.00M 10-Q · filed 2011-05-10 | $89.00M derived: sum of 2 quarters · filed 2011-05-10 | $114.00M derived: sum of 3 quarters · filed 2011-05-10 | ||
| 2010-12-31 | $35.00M derived: 10-Q 12 month − 10-Q 9 month · filed 2011-05-10 | $60.00M derived: sum of 2 quarters · filed 2011-05-10 | $38.00M 10-Q · filed 2011-05-10 | ||
| 2010-09-30 | $25.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $3.00M 10-Q · filed 2010-11-08 | |||
| 2010-06-30 | -$22.00M 10-Q · filed 2010-08-09 | ||||
| 2009-12-31 | $21.00M 10-K · filed 2011-02-25 | -$21.00M 10-Q · filed 2010-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |